latest news releases from the newsroom
OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology
WALTHAM, Mass., May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that results from a Phase 2 clinical trial of its vascular disrupting agent (VDA) product candidate, ZYBRESTAT (fosbretabulin), in women with platinum-resistant ovarian cancer, will be presented in a symposium at the upcoming 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL, June 1, 2009. In addition, an abstract describing clinical results from an ongoing Phase 1 trial in solid tumors of OXi4503, the Company's second-generation, dual-mechanism drug candidate, is published in the ASCO meeting program. OXiGENE will release a summary of presented results on June 1, 2009.
Photo Release -- SPOT Sponsored Climber Becomes the First Astronaut to Summit Everest
MILPITAS, Calif., May 20, 2009 (GLOBE NEWSWIRE) -- Today SPOT LLC, a wholly owned subsidiary of Globalstar Inc. (Nasdaq:GSAT), announces five-time Space Shuttle Astronaut and SPOT sponsored mountaineer Scott Parazynski made history, becoming the first man to have explored space and stand atop Mount Everest, the highest mountain on Earth at 29,029 feet (8,848 meters). Scott has been using his
Bob Evans Farms, Inc.
Bob Evans Farms Announces Quarterly Dividend
COLUMBUS, Ohio, May 20, 2009 (GLOBE NEWSWIRE) -- Bob Evans Farms, Inc. (Nasdaq:BOBE) today announced that its board of directors has declared a quarterly cash dividend of 16 cents ($0.16) per share on the company's outstanding common stock ($0.01 par value). The dividend is payable on June 15 to stockholders of record at the close of business on June 4.
Finkelstein Thompson LLP
Finkelstein Thompson LLP Announces Investigation of IDM Pharma, Inc.
WASHINGTON, May 20, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating potential shareholder claims arising from the proposed acquisition of IDM Pharma, Inc. ("IDM" or the "Company") (Nasdaq:IDMI) by Takeda Pharmaceutical Co. Under the terms of the merger agreement, IDM shareholders will receive $2.64 per share, valuing the transaction at approximately $66.7 million.
Finkelstein Thompson LLP
Finkelstein Thompson LLP Announces Investigation of D&E Communications, Inc.
WASHINGTON, May 20, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating potential claims against the board of directors of D&E Communications, Inc. ("D&E" or the "Company") (Nasdaq:DECC) arising out of their acquisition by Windstream Corp ("Windstream") (NYSE:WIN). Under the terms of the merger agreement, D&E shareholders will receive 0.650 shares of Windstream common stock and $5.00 in cash per each share of D&E common stock. Windstream expects to issue approximately 9.5 million shares of Windstream common stock valued at $86 million, based on Windstream's closing stock price on May 8, 2009, and pay approximately $73 million in cash as part of the transaction.